These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Pharmaceutical company-sponsored drug trials: what are we to believe? Shekelle P J Clin Epidemiol; 2010 Feb; 63(2):126-7. PubMed ID: 19836207 [No Abstract] [Full Text] [Related]
48. Fusing Randomized Trials With Big Data: The Key to Self-learning Health Care Systems? Angus DC JAMA; 2015 Aug; 314(8):767-8. PubMed ID: 26305643 [No Abstract] [Full Text] [Related]
49. Randomized clinical trials: slow death by a thousand unnecessary policies? Yusuf S CMAJ; 2004 Oct; 171(8):889-92; discussion 892-3. PubMed ID: 15477629 [No Abstract] [Full Text] [Related]
50. [Role of the methodology in cluster randomized trials]. Kramar A; Bonnetain F; Mathoulin-Pélissier S Bull Cancer; 2008 Dec; 95(12):1141-2. PubMed ID: 19108340 [No Abstract] [Full Text] [Related]
51. Sharing of Data From Industry-Funded Registered Clinical Trials. Boutron I; Dechartres A; Baron G; Li J; Ravaud P JAMA; 2016 Jun; 315(24):2729-30. PubMed ID: 27367768 [No Abstract] [Full Text] [Related]
52. Lag time in research to practice: are we reducing or increasing the gap? Fitzpatrick JJ Appl Nurs Res; 2008 Feb; 21(1):1. PubMed ID: 18226756 [No Abstract] [Full Text] [Related]
53. Bumps and bridges on the road to responsible sharing of clinical trial data. Berlin JA; Morris S; Rockhold F; Askie L; Ghersi D; Waldstreicher J Clin Trials; 2014 Feb; 11(1):7-12. PubMed ID: 24408901 [TBL] [Abstract][Full Text] [Related]
55. Learning What We Didn't Know - The SPRINT Data Analysis Challenge. Burns NS; Miller PW N Engl J Med; 2017 Jun; 376(23):2205-2207. PubMed ID: 28445656 [No Abstract] [Full Text] [Related]
56. Sample size determination and statistical power in randomized controlled trials. Sjögren P; Hedström L Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):652-3. PubMed ID: 20416528 [No Abstract] [Full Text] [Related]
57. [Are treatment effects or adverse effects of significance for the association between financing and conclusions in randomized trials?]. Als-Nielsen BE; Chen W; Gluud CN; Gluud LL Ugeskr Laeger; 2004 Apr; 166(18):1676-8. PubMed ID: 15174406 [No Abstract] [Full Text] [Related]
58. Reporting of power and sample size in randomized controlled trials. Burdick CO JAMA; 1995 Jan; 273(1):22. PubMed ID: 7996641 [No Abstract] [Full Text] [Related]
59. Reporting implementation in randomized trials: proposed additions to the consolidated standards of reporting trials statement. Mayo-Wilson E Am J Public Health; 2007 Apr; 97(4):630-3. PubMed ID: 17329641 [TBL] [Abstract][Full Text] [Related]
60. BIG DATA AND BIODIVERSITY. Filling in biodiversity threat gaps. Joppa LN; O'Connor B; Visconti P; Smith C; Geldmann J; Hoffmann M; Watson JE; Butchart SH; Virah-Sawmy M; Halpern BS; Ahmed SE; Balmford A; Sutherland WJ; Harfoot M; Hilton-Taylor C; Foden W; Di Minin E; Pagad S; Genovesi P; Hutton J; Burgess ND Science; 2016 Apr; 352(6284):416-8. PubMed ID: 27102469 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]